Global high content screening market is expected to witness lucrative market growth as a consequence of rising need for development of new drug molecules owing to presence of obsolete drug therapies with less potency. The increasing need is also attributed to rising prevalence of chronic diseases requiring intensive treatment such as HIV AIDS, epilepsy and Parkinson’s disease. Rising need of determination and study of toxicity levels in the initial phases of drug discovery is also high rendering impact driver of the high content screening market. Technological advancements including usage of multicolored fluorescence based reagents, polarization techniques, automated imaging technology and flow cytometry are anticipated to drive the market growth further. With advent of these advancements, unwanted toxicities during drug interactions are eliminated. This leads to increase stability of new drugs, greater accuracy, reduction in drug discovery time and increased cost efficiency and hence is expected to further boost the demand for the market. Moreover, better data visualization tools, improved software and new detection methods such as fluorescence lifetime & multispectral imaging are predicted to drive the growth. Furthermore, benefits associated with these innovations such as application in gene identification & neonatal development studies and enhanced penetrability of drug are anticipated to provide growth potential to the high content screening market over the forecast period.
View Summary Of This Report Click Here: www.grandviewresearch.com/industry-analysis/high-content-screening-market
The global high content screening market is segmented on the basis of product, end use and application. On the basis of product, it is segregated into consumables, microplates, instruments, software and service. On the basis of application, it is categorized into primary & secondary screening, compound profiling and target identification & validation. On the basis of end-use, it is segmented into contract research organizations, pharmaceutical & biotechnology companies and academic and research institutes. As of 2014, the high screening instrument segment held the substantial share in high content screening market owing to need for high cost efficient alternatives.
Geographically, high content screening market is segregated into North America, Europe, Asia Pacific, Latin America and MEA. As of 2014, North America held the largest share of the high content screening market owing to significant growth factors including increasing incidences of chronic diseases, rising prevalence of geriatric population, various collaborations with research institutes, high disposable income and advanced healthcare infrastructure.
Major players of high content screening market are Molecular Devices, Thermo Fisher Scientific, PerkinElmer Inc., Becton, GE Healthcare, Dickinson and Company, Merck KGaA, Cell Signaling Technology, Thorlabs, Inc., Genedata AG and Yokogawa Electric Corporation.
To learn more about this report: www.goo.gl/KDFv81
The global high content screening market is segmented on the basis of product, end use and application. On the basis of product, it is segregated into consumables, microplates, instruments, software and service. On the basis of application, it is categorized into primary & secondary screening, compound profiling and target identification & validation. On the basis of end-use, it is segmented into contract research organizations, pharmaceutical & biotechnology companies and academic and research institutes. As of 2014, the high screening instrument segment held the substantial share in high content screening market owing to need for high cost efficient alternatives.
Geographically, high content screening market is segregated into North America, Europe, Asia Pacific, Latin America and MEA. As of 2014, North America held the largest share of the high content screening market owing to significant growth factors including increasing incidences of chronic diseases, rising prevalence of geriatric population, various collaborations with research institutes, high disposable income and advanced healthcare infrastructure.
Major players of high content screening market are Molecular Devices, Thermo Fisher Scientific, PerkinElmer Inc., Becton, GE Healthcare, Dickinson and Company, Merck KGaA, Cell Signaling Technology, Thorlabs, Inc., Genedata AG and Yokogawa Electric Corporation.
To learn more about this report: www.goo.gl/KDFv81
No comments:
Post a Comment